Sirtex Medical and China Grand Pharmaceutical announce landmark drug registration milestone

Sirtex Y90

Sirtex Medical (“Sirtex”) is a leading manufacturer of targeted liver cancer therapies. It announced today that Sirtex and its shareholders have been issued a “Notice of Drug Clinical Trial Approval” by the National Medical Products Administration (NMPA) of the People’s Republic of China.

Also, Kevin R. Smith, Chief Executive Officer of Sirtex commented: “This is a critical milestone toward allowing us to provide a valuable treatment option to people with liver cancer in China.”

Read PR >>